
People with incurable melanomas and brain or breast cancers are to get injections of tumour-fighting viruses.
The trial will test the safety of aĀ virus that has been engineered to shrink tumours ā an approach that holds promise for a range ofĀ cancers, including deadly brainĀ tumours.
The idea of using viruses to kill cancers goes back more than a century, inspired by anecdotal reports of some people with viralĀ infections being cured of malignancies. But turning viruses that can infect and kill human cells into a safe and effective treatment that targets only tumour cells has proved tricky.
Advertisement
Researchers are making progress at last. In 2015, the US Food and Drug Administration approved the first ever virus-based cancer treatment ā a genetically modified herpes virus for advanced melanomas that canāt be completely removed by surgery. Many other virus-based treatments are in development.
Amin Hajitou at Imperial College London and his colleagues have come up with an unusual form of viral treatment, based on a phage ā a kind of virus that normally only attacks bacteria.
In principle, it should be safer to use engineered phages in people than viruses that normally infect humans. The phages are designed to bind to cancer cells and inject DNA into them, but these modified phages canāt replicate. This means that they canāt spread to healthy tissue, unlike viruses thatĀ normally attack humans.
Hajitou and his team developed thisĀ phage by giving it genetic instructions that enable it to bind to a protein often found on the outside of cancer cells, and then inject its DNA into them. They also gave it genes that code for toxic proteins. Once injected with these genes, cancer cells begin to make the proteins, and then die.
In tests in dogs, the phage shrank tumours and, in some cases, made them completely disappear. Hajitou says this phageĀ is now set to begin the firstĀ stages of human trials later this year. TheĀ trial will take place at the Rutgers Cancer Institute in New Jersey and involve volunteers whose breast, brain or melanoma cancers havenāt responded to other treatments.
Hajitou is already working onĀ aĀ more advanced version of theĀ phage treatment to target glioblastoma, a type of brain cancer with few treatment options. At the moment, around half the people diagnosed with it die within 15Ā months.
Glioblastoma cells often resist aĀ cancer drug called TMZ by activating genes that block it. Hajitouās team has taken the code for the genetic switch that fires up these genes, and added it to the engineered phages. This means that, when infected tumour cells try to use these genes to resist the drug, they will make even more of the toxic proteins.
Seek and destroy
When mice with human glioblastomas were given this phage and TMZ together, they survived for two months, whereas controls died after a month. The treated mice also lived longer than those given either the phageĀ or TMZ on its own. Human trials are still several years away, says Hajitou.
The phage is promising for brain cancers in particular because, after being injected intoĀ the bloodstream, it seeks outĀ tumours around the body andĀ can cross the blood-brain barrier. By contrast, most other experimental viral cancer treatments have to be injected directly into tumours.
It would be much easier to rollĀ out treatments that can be delivered by routine injections, says Alan Melcher at the Institute of Cancer Research in London.
This designer phage also doesnāt need to carry the genes forĀ replicating itself, so more DNAĀ can be engineered into it, upĀ to 20,000 letters of code. ThisĀ means there is scope for adding extra genes to enhance itsĀ effectiveness, while further DNA edits could enable the phageĀ to target other types ofĀ tumours.
EMBO Molecular Medicine